研究
2021 研究業績・論文発表
論文
A. Hamada, H. Oizumi, H. Kato, J. Suzuki, K. Nakahashi, S. Takamori, R. Sho and M. Sadahiro
Outcome of thoracoscopic anatomical sublobar resection under 3-dimensional computed tomography simulation
Surg Endosc, 2021
A. Hamada, K. Suda, T. Koga, T. Fujino, M. Nishino, S. Ohara, M. Chiba, M. Shimoji, T. Takemoto, J. Soh, T. Uchida and T. Mitsudomi
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
Lung Cancer, 2021
T. Fujino, K. Suda, K.Sakai, I. Murakami, S. Shimizu, S. Ohara, T. Koga, A. Hamada, J. Soh, K. Nishio, and T. Mitsudomi.
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas
Clin Lung Cancer, 2021
T. Koga, K. Suda, M. Nishino, T. Fujino, S. Ohara, A. Hamada, J. Soh, V. Tirunagaru, A. Vellanki, R. C. Doebele and T. Mitsudomi
Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
Transl Lung Cancer Res, 2021
K. Suda
Recent Advances in Cancer Immunotherapy
Biomolecules, 2021
K. Suda, S. Ohara, T. Fujino, A. Hamada, M Chiba, M. Shimoji, T. Takemoto, J. Soh and T. Mitsudomi
Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer
Clin Lung Cancer, 2021
J. Soh, S. Sugimoto, K. Namba, A. Miura, T. Shiotani, H. Yamamoto, K. Suzawa, K. Shien, H. Yamamoto, M. Okazaki, K. Katsui, M. Yamane, K. Kiura, S. Kanazawa and S. Toyooka
Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer
Ann Thorac Surg, 2021
H. Tada, T. Mitsudomi, T. Misumi, K. Sugio, M. Tsuboi, I. Okamoto, Y. Iwamoto, N. Sakakura, S. Sugawara, S. Atagi, T. Takahashi, H. Hayashi, M. Okada, H. Inokawa, H. Yoshioka, K. Takahashi, M. Higashiyama, I. Yoshino, K. Nakagawa and G. West Japan Oncology
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
J Clin Oncol, 2021
T. Fujino and T. Mitsudomi
Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
JTO Clinical and Research Reports (2021) 2: 100134.
T. Fujino, K. Suda and T. Mitsudomi
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
Lung Cancer (Auckl) (2021) 12: 35-50.
A. Hamada, J. Soh, A. Hata, K. Nakamatsu, M. Shimokawa, Y. Yatabe, H. Oizumi, M. Tsuboi, H. Horinouchi, I. Yoshino, M. Tanahashi, S. Toyooka, M. Okada, H. Yokomise, M. Yamashita, Y. Nishimura, N. Yamamoto, K. Nakagawa and T. Mitsudomi
Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L)
Clin Lung Cancer (2021)
A. Hamada, J. Soh and T. Mitsudomi
Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
Transl Lung Cancer Res (2021) 10: 555-562.
T. Koga, K. Suda, T. Fujino, S. Ohara, A. Hamada, M. Nishino, M. Chiba, M. Shimoji, T. Takemoto, T. Arita, M. Gmachl, M. H. Hofmann, J. Soh and T. Mitsudomi
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
J Thorac Oncol (2021) 16: 1321-1332.
T. Mitsudomi and J. Soh
Adjuvant therapy of operable nonsmall cell lung cancer: an update
Curr Opin Oncol (2021) 33: 47-54.
M. Nishino, K. Suda, T. Koga, S. Ohara, T. Fujino, J. Soh, V. Tirunagaru, A. Vellanki, R. C. Doebele and T. Mitsudomi
Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance
Thorac Cancer (2021) 12: 1511-1516.
S. Ohara, K. Suda, T. Fujino, A. Hamada, T. Koga, M. Nishino, M. Chiba, M. Shimoji, T. Takemoto, J. Soh and T. Mitsudomi
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer
Lung Cancer (2021) 154: 84-91.
S. Ohara, K. Suda and T. Mitsudomi
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations
Cells (2021) 10:
J. Soh, A. Hamada, T. Fujino and T. Mitsudomi
Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Cancers (Basel) (2021) 13:
K. Suda and T. Mitsudomi
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
Cells (2021) 10:
K. Suda, T. Mitsudomi, Y. Shintani, J. Okami, H. Ito, T. Ohtsuka, S. Toyooka, T. Mori, S. I. Watanabe, H. Asamura, M. Chida, H. Date, S. Endo, T. Nagayasu, R. Nakanishi, E. Miyaoka, M. Okumura, I. Yoshino and R. Japanese Joint Committee of Lung Cancer
Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases
Ann Thorac Surg (2021) 111: 269-276.
K. Suda, K. Sakai, K. Obata, S. Ohara, T. Fujino, T. Koga, A. Hamada, J. Soh, K. Nishio and T. Mitsudomi
Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases
Clin Lung Cancer (2021) 22: e141-e145.
T. Takemoto, J. Soh, S. Ohara, T. Fujino, T. Koga, M. Nishino, A. Hamada, M. Chiba, M. Shimoji, K. Suda, K. Tomizawa and T. Mitsudomi
The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery
Surg Today (2021) 51: 1480-1487.